Home Diagnostic Testing

PG-Seq™ Rapid Non-Invasive Preimplantation Genetic Testing Kit as Alternative to IVF Embryo Biopsies

Launched by PerkinElmer

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today introduced its PG-Seq™ Rapid Non-Invasive Preimplantation Genetic Testing for Aneuploidy (PGT-A) kit. This solution tests spent embryo culture media for chromosomal abnormalities during in vitro fertilization (IVF) treatment.

PGT-A is used to identify viable embryos, so the transfer or storage of embryos with an incorrect number of chromosomes can be avoided, as those typically lead to failed IVF cycles. Traditionally, PGT-A requires a biopsy of a developing embryo by creating an opening in the outer coating prior to removal and testing of a few cells. However, recent studies have shown that an embryo releases small amounts of DNA into the culture media in which it is growing, allowing the surrounding fluid to be genetically tested instead.

PerkinElmer’s PG-Seq Rapid Non-Invasive PGT-A kit is specifically designed for this type of sample, which enables embryos to remain fully intact. Leveraging the science behind PerkinElmer’s biopsy-based PG-Seq kit 2.0, the new non-invasive kit tests the spent embryo culture media to accurately detect aneuploidies, as well as structural rearrangements, including unbalanced translocations and segmental errors.

The kit is a modified version of the new PG-Seq Rapid kit, a three-hour sample preparation workflow—less than half of the sample preparation time compared to the PG-Seq kit 2.0 workflow.

“Data from a global network of 15 laboratories who have provided samples, shows it is possible to achieve more than 90% correlation between results of biopsied embryo and spent embryo culture media with the PG-Seq Rapid Non-Invasive PGT kit,” said Masoud Toloue, Ph.D., vice president, Diagnostics, PerkinElmer. “By eliminating the risks associated with performing a cell biopsy, PGT-A becomes more broadly accessible. IVF providers can significantly increase the likelihood of successful embryo transfers and reduce time to pregnancy.”

“From what we’ve observed so far, the results look excellent, and we are looking forward to further developing our non-invasive PGT program,” said Manuel Viotti, PhD, senior scientist, Zouves Foundation for Reproductive Medicine, Zouves Fertility Center.

Exit mobile version